Evidence map›Paper›PMID 41078713›Full record

ArticleOncology letters2025

Serum fucosylated receptor expression-enhancing protein 5 as a biomarker for early stage pancreatic cancer.

Kazuyuki Sogawa, Riko Yonekubo, Momori Shimizu, Satoshi Muraoka, Jun Adachi, Shigetsugu Takano, Hirotaka Takizawa, Masayuki Ohtsuka, Takeshi Tomonaga

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuyuki SogawaDepartment of Molecular Diagnosis, Graduate School of Environmental Health, Azabu University, Sagamihara, Kanagawa 252-5201, Japan.
Riko YonekuboDepartment of Biochemistry, School of Life and Environmental Science, Azabu University, Sagamihara, Kanagawa 252-5201, Japan.
Momori ShimizuDepartment of Biochemistry, School of Life and Environmental Science, Azabu University, Sagamihara, Kanagawa 252-5201, Japan.
Satoshi MuraokaLaboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.
Jun AdachiLaboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.
Shigetsugu TakanoDepartment of General Surgery, Graduate School of Medicine, Chiba University, Chuo, Chiba 260-8677, Japan.
Hirotaka TakizawaKashiwado Clinic in Port-Square, Kashiwado Memorial Foundation, Chuo, Chiba 260-0025, Japan.
Masayuki OhtsukaDepartment of General Surgery, Graduate School of Medicine, Chiba University, Chuo, Chiba 260-8677, Japan.
Takeshi TomonagaLaboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and is a leading cause of cancer mortality. Early diagnosis is difficult due to the anatomical characteristics of the pancreas, which is a long and thin organ located dorsal to the stomach and large intestine. The aim of the present study was to search for protein biomarkers for PDAC in serum extracellular vesicles (EVs) using mass spectrometry, and to validate identified biomarkers using an enzyme-linked immunosorbent assay (ELISA) of sera from patients. Comprehensive and targeted proteomic analyses for biomarker discovery and verification were performed using EVs from serum of patients with PDAC, patients with chronic pancreatitis (PT) and healthy volunteers (HVs). For validation, the discriminatory power of candidate proteins was evaluated using an ELISA. Of the 3,043 proteins analyzed, 45 were identified as potential biomarkers, with receptor expression-enhancing protein 5 (REEP5) selected for further analysis. The serum level of fucosylated REEP5 was significantly higher in PDAC cases compared with in PT and HVs (P<0.001). The areas under the curve (AUC) of the receiver operator characteristic were 0.928 for fucosylated REEP5 and 0.805 for carbohydrate antigen 19-9 (CA19-9) in PDAC vs. non-cancer controls. The AUCs were 0.962 for fucosylated REEP5 and 0.810 for CA19-9 in stages I and II of PDAC. These results indicate that fucosylated REEP5 is a novel serum EV biomarker for detection of early stage PDAC. Further analysis in a larger cohort is warranted to evaluate the clinical utility of fucosylated REEP5 as a biomarker for PDAC.

Indexed as

biomarkerextracellular vesiclespancreatic cancerreceptor expression-enhancing protein 5serum

Identifiers

PMID41078713
PMCPMC12511925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.